Cell-Penetrating Compstatin Analogs and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2014/027289, filed Mar 14, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,941,184 | Cell-Penetrating Compstatin Analogs and Uses Thereof In force · High confidence | Apellis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,407,789 | Cell-Penetrating Compstatin Analogs and Uses Thereof In force · High confidence | Apellis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,308,687 | Cell-Penetrating Compstatin Analogs and Uses Thereof In force · High confidence | Apellis Pharmaceuticals, Inc. | In force | High confidence | ||
| Application 17/852,439 | Cell-Penetrating Compstatin Analogs and Uses Thereof Abandoned Abandoned Mar 15, 2024 | Apellis Pharmaceuticals, Inc. | Abandoned | Abandoned Mar 15, 2024 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Apellis Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.